Phase 3 Stroke Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older who have had an ischemic stroke (a stroke caused by a blockage) with a large blood vessel blockage in the brain, confirmed by a CT or MRI scan of specific arteries (the internal carotid artery or the main middle brain artery)
• People who are being treated with a clot-removal procedure (thrombectomy) within 24 hours of their stroke starting
• People whose stroke started 0–6 hours ago and whose brain scan shows enough healthy brain tissue remaining (an ASPECTS score of 3 or higher on the standard CT scan)
• People whose stroke started 6–24 hours ago and whose specialised brain scan shows a smaller affected area of less than 100ml
• People whose qualifying brain scan was done within 4 hours of being enrolled in the trial (if transferred from another hospital, a repeat CT scan may be needed)
• People who were largely independent before their stroke, with only mild or no pre-existing disability (a Modified Rankin Scale score of 2 or less)
• People for whom the legal consent requirements in their location have been met

Who may not be able to join:

• People who have bleeding in the brain, as shown on a CT or MRI scan
• People whose brain scan shows very extensive stroke damage (an ASPECTS score of 0–2)
• People whose specialised brain scan shows a large affected area of more than 100ml, when their stroke started 6–24 hours ago
• People who are expected to need a stent placed in the blood vessels of the brain or neck during their procedure
• People for whom more than six attempts have already been made to remove the clot in the same blood vessel
• People who received the clot-dissolving drug alteplase within 30 minutes before the trial drug would be given
• People who cannot have contrast dye used during imaging scans
• People who, in the medical team's judgement, have a condition that could make the trial treatment unsafe (confirm with trial site)
• Women who are pregnant
• People currently participating in another research study that involves experimental treatments beyond standard care
• People taking blood-thinning medications in certain circumstances — though people on warfarin with an INR of 1.7 or below, or people on dabigatran who have received a reversal treatment called idarucizumab, may still be considered
• People who have other standard medical reasons that would normally prevent the use of clot-dissolving treatments (confirm with trial site)
• People with a known terminal illness where survival beyond one year would not be expected
• People for whom withdrawal of active medical care or comfort-only care is already planned

Important: Always verify eligibility with the trial site directly before applying.